Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM

BMC Immunology

Volumn 16, Issue 1, 2015, Pages

  Deng, Zhenling ^a   Wu, Yanhong ^a   Ma, Wenbo ^a   Zhang, Shuren ^a   Zhang, Yu Qian ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Adoptive T cell transfer; Cancer stem cell; Chimeric antigen receptor; EpCAM; Prostate cancer

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CELL PROLIFERATION; CELL SELECTION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUMINESCENCE; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PERIPHERAL LYMPHOCYTE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CANCER STEM CELL; CELL GROWTH; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PROSTATIC NEOPLASMS; SCID MOUSE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL CELL ADHESION MOLECULE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923912770     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/s12865-014-0064-x     Document Type: Article

References (20)

1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-57.
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299-308.
3. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Investig. 2007;117(6):1466-76.
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9.
5. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825-33.
6. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755-68.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983-8.
8. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer. 2009;9(2):143. author reply 143.
9. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030-7.
10. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106-10.
11. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111-5.
12. Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012;31(3-4):779-91.
13. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, et al. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013;45(12):2736-48.
14. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol. 2003;33(5):1334-40.
15. Zheng Z, Chinnasamy N, Morgan RA. Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry. J Transl Med. 2012;10:29.
16. Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689-702.
17. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 1993;11:385-402.
18. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse effect following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-51.
19. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-20.
20. Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther. 2010;18(4):692-9.